Found 16 results
Author Title Type [ Year(Desc)]
Filters: Author is Wu, M  [Clear All Filters]
1987
L. E. Bermudez, Wu, M., and Young, L. S., “Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin.”, The Journal of infectious diseases, vol. 156, no. 3, pp. 510-3, 1987.
1989
L. E. Bermudez, Wu, M., Enkel, H., and Young, L. S., “Naturally occurring antibodies against Mycobacterium avium complex.”, Annals of clinical and laboratory science, vol. 19, no. 6, pp. 435-43, 1989.
L. E. Bermudez, Stevens, P., Kolonoski, P., Wu, M., and Young, L. S., “Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor.”, Journal of immunology (Baltimore, Md. : 1950), vol. 143, no. 9, pp. 2996-3000, 1989.
1990
L. E. Bermudez, Wu, M., and Young, L. S., “Effect of stress-related hormones on macrophage receptors and response to tumor necrosis factor.”, Lymphokine research, vol. 9, no. 2, pp. 137-45, 1990.
L. E. Bermudez, Martinelli, J. C., Gascon, R., Wu, M., and Young, L. S., “Protection against gram-negative bacteremia in neutropenic mice with recombinant granulocyte-macrophage colony-stimulating factor.”, Cytokine, vol. 2, no. 4, pp. 287-93, 1990.
1991
L. E. Bermudez, Wu, M., Martinelli, J., and Young, L. S., “Ethanol affects release of TNF and GM-CSF and membrane expression of TNF receptors by human macrophages.”, Lymphokine and cytokine research, vol. 10, no. 5, pp. 413-9, 1991.
1992
L. E. Bermudez, Wu, M., Petrofsky, M., and Young, L. S., “Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages.”, Infection and immunity, vol. 60, no. 10, pp. 4245-52, 1992.
L. E. Bermudez, Wu, M., Young, L. S., and Inderlied, C. B., “Postantibiotic effect of amikacin and rifapentine against Mycobacterium avium complex.”, The Journal of infectious diseases, vol. 166, no. 4, pp. 923-6, 1992.
1994
C. B. Inderlied, Barbara-Burnham, L., Wu, M., Young, L. S., and Bermudez, L. E., “Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages.”, Antimicrobial agents and chemotherapy, vol. 38, no. 8, pp. 1838-43, 1994.
1995
L. E. Bermudez, Wu, M., and Young, L. S., “Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium.”, Infection and immunity, vol. 63, no. 10, pp. 4099-104, 1995.
1996
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Wu, M., Barbara-Burnham, L., and Young, L. S., “Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice.”, Antimicrobial agents and chemotherapy, vol. 40, no. 3, pp. 546-51, 1996.
1998
L. E. Bermudez, Petrofsky, M., Wu, M., and Young, L. S., “Clarithromycin significantly improves interleukin-12-mediated anti-Mycobacterium avium activity and abolishes toxicity in mice.”, The Journal of infectious diseases, vol. 178, no. 3, pp. 896-9, 1998.
1999
L. E. Bermudez, Wu, M., Miltner, E., and Inderlied, C. B., “Isolation of two subpopulations of Mycobacterium avium within human macrophages.”, FEMS microbiology letters, vol. 178, no. 1, pp. 19-26, 1999.
L. E. Bermudez, Kolonoski, P., Wu, M., Aralar, P. A., Inderlied, C. B., and Young, L. S., “Mefloquine is active in vitro and in vivo against Mycobacterium avium complex.”, Antimicrobial agents and chemotherapy, vol. 43, no. 8, pp. 1870-4, 1999.
2001
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Petrofsky, M., Aralar, P., Wu, M., and Young, L. S., “Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.”, Antimicrobial agents and chemotherapy, vol. 45, no. 1, pp. 217-22, 2001.
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Wu, M., Aralar, P., and Young, L. S., “Telithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatment.”, Antimicrobial agents and chemotherapy, vol. 45, no. 8, pp. 2210-4, 2001.